Endocrinology and Metabolism

Original Articles

Impact of Antidiabetic Drugs on Clinical Outcomes of COVID-19: A Nationwide Population-Based Study: Han Na Jang, Sun Joon Moon, Jin Hyung Jung, Kyung-Do Han, Eun-Jung Rhee, Won-Young Lee; Received October 16, 2023 Accepted January 3, 2024 Published online January 29, 2024; DOI: https://doi.org/10.3803/EnM.2024.1857 [Epub ahead of print]

838 View
39 Download

Abstract PDF PubReader ePub: Background
Inconsistent results have been reported regarding the association between the use of antidiabetic drugs and the clinical outcomes of coronavirus disease 2019 (COVID-19). This study aimed to investigate the effect of antidiabetic drugs on COVID-19 outcomes in patients with diabetes using data from the National Health Insurance Service (NHIS) in South Korea.
Methods
We analyzed the NHIS data of patients aged ≥20 years who tested positive for COVID-19 and were taking antidiabetic drugs between December 2019 and June 2020. Multiple logistic regression analysis was performed to analyze the clinical outcomes of COVID-19 based on the use of antidiabetic drugs.
Results
A total of 556 patients taking antidiabetic drugs tested positive for COVID-19, including 271 male (48.7%), most of whom were in their sixties. Of all patients, 433 (77.9%) were hospitalized, 119 (21.4%) received oxygen treatment, 87 (15.6%) were admitted to the intensive care unit, 31 (5.6%) required mechanical ventilation, and 61 (11.0%) died. Metformin was significantly associated with the lower risks of mechanical ventilation (odds ratio [OR], 0.281; 95% confidence interval [CI], 0.109 to 0.720; P=0.008), and death (OR, 0.395; 95% CI, 0.182 to 0.854; P=0.018). Dipeptidylpeptidase-4 inhibitor (DPP-4i) were significantly associated with the lower risks of oxygen treatment (OR, 0.565; 95% CI, 0.356 to 0.895; P=0.015) and death (OR, 0.454; 95% CI, 0.217 to 0.949; P=0.036). Sulfonylurea was significantly associated with the higher risk of mechanical ventilation (OR, 2.579; 95% CI, 1.004 to 6.626; P=0.049).
Conclusion
In patients with diabetes and COVID-19, metformin exhibited reduced risks of mechanical ventilation and death, DPP- 4i was linked with lower risks of oxygen treatment and death, while sulfonylurea was related to the increased risk of mechanical ventilation.

Diabetes, obesity and metabolism Big Data Articles (National Health Insurance Service Database)
Risk for Newly Diagnosed Type 2 Diabetes Mellitus after COVID-19 among Korean Adults: A Nationwide Matched Cohort Study: Jong Han Choi, Kyoung Min Kim, Keeho Song, Gi Hyeon Seo; Endocrinol Metab. 2023;38(2):245-252. Published online April 5, 2023; DOI: https://doi.org/10.3803/EnM.2023.1662

2,234 View
119 Download
2 Web of Science
2 Crossref

Background
Coronavirus disease 2019 (COVID-19) can cause various extrapulmonary sequelae, including diabetes. However, it is unclear whether these effects persist 30 days after diagnosis. Hence, we investigated the incidence of newly diagnosed type 2 diabetes mellitus (T2DM) in the post-acute phase of COVID-19.
Methods
This cohort study used data from the Health Insurance Review and Assessment Service, a representative national healthcare database in Korea. We established a cohort of 348,180 individuals diagnosed with COVID-19 without a history of diabetes between January 2020 and September 2021. The control group consisted of sex- and age-matched individuals with neither a history of diabetes nor COVID-19. We assessed the hazard ratios (HR) of newly diagnosed T2DM patients with COVID-19 compared to controls, adjusted for age, sex, and the presence of hypertension and dyslipidemia.
Results
In the post-acute phase, patients with COVID-19 had an increased risk of newly diagnosed T2DM compared to those without COVID-19 (adjusted HR, 1.30; 95% confidence interval [CI], 1.27 to 1.33). The adjusted HRs of non-hospitalized, hospitalized, and intensive care unit-admitted patients were 1.14 (95% CI, 1.08 to 1.19), 1.34 (95% CI, 1.30 to 1.38), and 1.78 (95% CI, 1.59 to 1.99), respectively. The risk of T2DM in patients who were not administered glucocorticoids also increased (adjusted HR, 1.29; 95% CI, 1.25 to 1.32).
Conclusion
COVID-19 may increase the risk of developing T2DM beyond the acute period. The higher the severity of COVID-19 in the acute phase, the higher the risk of newly diagnosed T2DM. Therefore, T2DM should be included as a component of managing long-term COVID-19.

Citations

Citations to this article as recorded by

New-Onset Diabetes Mellitus in COVID-19: A Scoping Review
Anca Pantea Stoian, Ioana-Cristina Bica, Teodor Salmen, Wael Al Mahmeed, Khalid Al-Rasadi, Kamila Al-Alawi, Maciej Banach, Yajnavalka Banerjee, Antonio Ceriello, Mustafa Cesur, Francesco Cosentino, Alberto Firenze, Massimo Galia, Su-Yen Goh, Andrej Janez,
Diabetes Therapy.2024; 15(1): 33. CrossRef
Pituitary Diseases and COVID-19 Outcomes in South Korea: A Nationwide Cohort Study
Jeonghoon Ha, Kyoung Min Kim, Dong-Jun Lim, Keeho Song, Gi Hyeon Seo
Journal of Clinical Medicine.2023; 12(14): 4799. CrossRef

Thyroid
Insights from a Prospective Follow-up of Thyroid Function and Autoimmunity among COVID-19 Survivors: David Tak Wai Lui, Chi Ho Lee, Wing Sun Chow, Alan Chun Hong Lee, Anthony Raymond Tam, Carol Ho Yi Fong, Chun Yiu Law, Eunice Ka Hong Leung, Kelvin Kai Wang To, Kathryn Choon Beng Tan, Yu Cho Woo, Ching Wan Lam, Ivan Fan Ngai Hung, Karen Siu Ling Lam; Endocrinol Metab. 2021;36(3):582-589. Published online June 8, 2021; DOI: https://doi.org/10.3803/EnM.2021.983

10,838 View
265 Download
32 Web of Science
34 Crossref

Abstract PDF PubReader ePub

Background
The occurrence of Graves’ disease and Hashimoto thyroiditis after coronavirus disease 2019 (COVID-19) raised concerns that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may trigger thyroid autoimmunity. We aimed to address the current uncertainties regarding incident thyroid dysfunction and autoimmunity among COVID-19 survivors.
Methods
We included consecutive adult COVID-19 patients without known thyroid disorders, who were admitted to Queen Mary Hospital from July 21 to September 21, 2020 and had serum levels of thyroid-stimulating hormone, free thyroxine, free triiodothyronine (fT3), and anti-thyroid antibodies measured both on admission and at 3 months.
Results
In total, 122 patients were included. Among 20 patients with abnormal thyroid function tests (TFTs) on admission (mostly low fT3), 15 recovered. Among 102 patients with initial normal TFTs, two had new-onset abnormalities that could represent different phases of thyroiditis. Among 104 patients whose anti-thyroid antibody titers were reassessed, we observed increases in anti-thyroid peroxidase (TPO) (P<0.001) and anti-thyroglobulin (P<0.001), but not anti-thyroid stimulating hormone receptor titers (P=0.486). Of 82 patients with negative anti-TPO findings at baseline, 16 had a significant interval increase in anti-TPO titer by >12 U, and four became anti-TPO-positive. Worse baseline clinical severity (P=0.018), elevated C-reactive protein during hospitalization (P=0.033), and higher baseline anti-TPO titer (P=0.005) were associated with a significant increase in anti-TPO titer.
Conclusion
Most patients with thyroid dysfunction on admission recovered during convalescence. Abnormal TFTs suggestive of thyroiditis occurred during convalescence, but infrequently. Importantly, our novel observation of an increase in anti-thyroid antibody titers post-COVID-19 warrants further follow-up for incident thyroid dysfunction among COVID-19 survivors.

Citations

Citations to this article as recorded by

The prevalence of thyroid disorders in COVID-19 patients: a systematic review and meta-analysis
Sadra Ashrafi, Hossein Hatami, Razieh Bidhendi-Yarandi, Mohammad Hossein Panahi
BMC Endocrine Disorders.2024;[Epub] CrossRef
Does COVID-19 affect thyroid more than non-COVID-19 infections? A retrospective study
Yasemin Ucal, Muhittin Serdar, Hande Karpuzoğlu, Neval Yurttutan Uyar, Meltem Kilercik, Mustafa Serteser, Aysel Ozpinar
Turkish Journal of Biochemistry.2024;[Epub] CrossRef
Thyroiditis and COVID-19: focus on pediatric age. A narrative review
F. d’Aniello, M. E. Amodeo, A. Grossi, G. Ubertini
Journal of Endocrinological Investigation.2024;[Epub] CrossRef
The most common persistent symptoms in patients with COVID-19 who were evaluated in the Internal Medicine polyclinic
Zeynep KOÇ, Seydahmet AKIN
The European Research Journal.2023; 9(1): 97. CrossRef
Clinical assessment of children with long COVID syndrome
Réka Garai, Péter Krivácsy, Vivien Herczeg, Fanni Kovács, Bálint Tél, Judit Kelemen, Anna Máthé, Eszter Zsáry, Johanna Takács, Dániel Sándor Veres, Attila J. Szabó
Pediatric Research.2023; 93(6): 1616. CrossRef
T Cell Receptor Sequences Amplified during Severe COVID-19 and Multisystem Inflammatory Syndrome in Children Mimic SARS-CoV-2, Its Bacterial Co-Infections and Host Autoantigens
Robert Root-Bernstein, Elizabeth Churchill, Shelby Oliverio
International Journal of Molecular Sciences.2023; 24(2): 1335. CrossRef
A Literature Review on SARS-CoV-2 and Other Viruses in Thyroid Disorders: Environmental Triggers or No-Guilty Bystanders?
Francesca Gorini, Cristina Vassalle
International Journal of Environmental Research and Public Health.2023; 20(3): 2389. CrossRef
Thyroid dysfunction as a long-term post-COVID-19 complication in mild-to-moderate COVID-19
Vesselina Yanachkova, Teodora Stankova, Radiana Staynova
Biotechnology & Biotechnological Equipment.2023; 37(1): 194. CrossRef
The Influence of SARS-CoV-2 Infection on the Thyroid Gland
Aleksandra Piekarska, Marta Góral, Marta Kozula, Aleksandra Jawiarczyk-Przybyłowska, Katarzyna Zawadzka, Marek Bolanowski
Biomedicines.2023; 11(2): 614. CrossRef
Thyroid Function Abnormalities and Outcomes in Hospitalized Patients with COVID-19 Infection: A Cross-Sectional Study
Deepika Patel, Dukhabandhu Naik, Sadishkumar Kamalanathan, Kadhiravan Tamilarasu, Jayaprakash Sahoo, Ayan Roy, Chandhana Merugu, Varun Suryadevara
Hormone and Metabolic Research.2023; 55(03): 169. CrossRef
The Spectrum of Thyroid Function Tests and Autoantibodies During Hospitalization and After Six Months of Discharge in COVID-19 Patients: Does COVID-19 Trigger Autoimmunity?
Ziynet Alphan Uc, Pinar Yagcı, Zelal Adibelli, Cevdet Duran
Endocrine Research.2023; 48(2-3): 44. CrossRef
Increased prevalence of autoimmune thyroid disease after COVID-19: A single-center, prospective study
Alessandro Rossini, Sara Cassibba, Francesca Perticone, Simone Vasilij Benatti, Serena Venturelli, Greta Carioli, Arianna Ghirardi, Marco Rizzi, Tiziano Barbui, Roberto Trevisan, Silvia Ippolito
Frontiers in Endocrinology.2023;[Epub] CrossRef
A prospective follow-up of thyroid volume and thyroiditis features on ultrasonography among survivors of predominantly mild to moderate COVID-19
Man Him Matrix Fung, David Tak Wai Lui, Keith Wan Hang Chiu, Sherman Haynam Lee, Chi Ho Lee, Wing Sun Chow, Alan Chun Hong Lee, Anthony Raymond Tam, Polly Pang, Tip Yin Ho, Carol Ho Yi Fong, Connie Hong Nin Loong, Chun Yiu Law, Kelvin Kai Wang To, Ching W
PeerJ.2023; 11: e15034. CrossRef
Study on Clinicopathological Features and Risk Factors of Patients with Multiple Primary Breast Cancers and Thyroid Disease
Jie Li, Yonghong Liu, Jian Jin, Qingfeng Shi, Yanting Ji, Bo Zhang, Pengfei Hu, Jinghua Pan
Mediators of Inflammation.2023; 2023: 1. CrossRef
Beyond Acute COVID-19: Investigating the Incidence of Subacute Thyroiditis in Long COVID-19 in Korea
Jeongmin Lee, Gi Hyeon Seo, Keeho Song
Endocrinology and Metabolism.2023; 38(4): 455. CrossRef
Thyroid Autoimmunity and SARS-CoV-2 Infection
Poupak Fallahi, Giusy Elia, Francesca Ragusa, Sabrina Rosaria Paparo, Armando Patrizio, Eugenia Balestri, Valeria Mazzi, Salvatore Benvenga, Gilda Varricchi, Laura Gragnani, Chiara Botrini, Enke Baldini, Marco Centanni, Clodoveo Ferri, Alessandro Antonell
Journal of Clinical Medicine.2023; 12(19): 6365. CrossRef
Autoimmune complications of COVID‐19
Niloufar Yazdanpanah, Nima Rezaei
Journal of Medical Virology.2022; 94(1): 54. CrossRef
The Independent Association of TSH and Free Triiodothyronine Levels With Lymphocyte Counts Among COVID-19 Patients
David Tak Wai Lui, Chi Ho Lee, Wing Sun Chow, Alan Chun Hong Lee, Anthony Raymond Tam, Polly Pang, Tip Yin Ho, Chloe Yu Yan Cheung, Carol Ho Yi Fong, Chun Yiu Law, Kelvin Kai Wang To, Ching Wan Lam, Kathryn Choon Beng Tan, Yu Cho Woo, Ivan Fan Ngai Hung,
Frontiers in Endocrinology.2022;[Epub] CrossRef
Comment on Khunti et al. COVID-19, Hyperglycemia, and New-Onset Diabetes. Diabetes Care 2021;44:2645–2655
Carmine Gazzaruso, Adriana Coppola, Pietro Gallotti, Ileana Terruzzi, Tiziana Montalcini, Livio Luzi
Diabetes Care.2022; 45(2): e45. CrossRef
The potential impact of COVID-19 on thyroid gland volumes among COVID-19 survivors
Emre Urhan, Zuleyha Karaca, Canan Sehit Kara, Zeynep Ture Yuce, Kursad Unluhizarci
Endocrine.2022; 76(3): 635. CrossRef
Systematic review of COVID-19 and autoimmune thyroiditis
Esra Tutal, Resat Ozaras, Hakan Leblebicioglu
Travel Medicine and Infectious Disease.2022; 47: 102314. CrossRef
The New Entity of Subacute Thyroiditis amid the COVID-19 Pandemic: From Infection to Vaccine
Mihaela Popescu, Adina Ghemigian, Corina Maria Vasile, Andrei Costache, Mara Carsote, Alice Elena Ghenea
Diagnostics.2022; 12(4): 960. CrossRef
Should we expect a wave of type 1 diabetes following SARS‐CoV‐2 pandemic?
Laura Montefusco, Andrea Mario Bolla, Paolo Fiorina
Diabetes/Metabolism Research and Reviews.2022;[Epub] CrossRef
COVID-19 and Thyroid Function: A Bi-Directional Two-Sample Mendelian Randomization Study
Gloria Hoi-Yee Li, Ching-Man Tang, Ching-Lung Cheung
Thyroid.2022; 32(9): 1037. CrossRef
Development of a prediction score (ThyroCOVID) for identifying abnormal thyroid function in COVID-19 patients
D. T. W. Lui, C. H. Lee, W. S. Chow, A. C. H. Lee, A. R. Tam, C. Y. Y. Cheung, C. H. Y. Fong, S. T. M. Kwok, C. Y. Law, K. K. W. To, C. W. Lam, K. C. B. Tan, Y. C. Woo, I. F. N. Hung, K. S. L. Lam
Journal of Endocrinological Investigation.2022; 45(11): 2149. CrossRef
Symptomatic Bradycardia Manifesting as Acute Hypothyroidism Following COVID-19 Infection: A Case Report
Jaydip Desai, Arsh N Patel, Courtney L Evans, Molly Triggs, Fulton Defour
Cureus.2022;[Epub] CrossRef
Schilddrüse und SARS-CoV-2
Georg Zettinig
Journal für Klinische Endokrinologie und Stoffwechsel.2022; 15(3): 100. CrossRef
Thyroid diseases are associated with coronavirus disease 2019 infection
Yutian Tian, Junyu Zhao, Tingting Wang, Haipeng Wang, Jinming Yao, Song Wang, Yaru Mou
Frontiers in Endocrinology.2022;[Epub] CrossRef
Thyrotropin Levels in Patients with Coronavirus Disease 2019: Assessment during Hospitalization and in the Medium Term after Discharge
Abdallah Al-Salameh, Noémie Scherman, Imane Adda, Juliette André, Yoann Zerbib, Julien Maizel, Jean-Daniel Lalau, Etienne Brochot, Claire Andrejak, Rachel Desailloud
Life.2022; 12(12): 2014. CrossRef
Long COVID in Patients With Mild to Moderate Disease: Do Thyroid Function and Autoimmunity Play a Role?
David Tak Wai Lui, Chi Ho Lee, Wing Sun Chow, Alan Chun Hong Lee, Anthony Raymond Tam, Polly Pang, Tip Yin Ho, Carol Ho Yi Fong, Chun Yiu Law, Eunice Ka Hong Leung, Kelvin Kai Wang To, Kathryn Choon Beng Tan, Yu Cho Woo, Ching Wan Lam, Ivan Fan Ngai Hung,
Endocrine Practice.2021; 27(9): 894. CrossRef
Hashimoto’s thyroiditis following SARS-CoV-2 infection
Rafael Silvestre Knack, Taliê Hanada, Renata Silvestre Knack, Kamilla Mayr
BMJ Case Reports.2021; 14(8): e244909. CrossRef
Higher SARS-CoV-2 viral loads correlated with smaller thyroid volumes on ultrasound among male COVID-19 survivors
David Tak Wai Lui, Matrix Man Him Fung, Keith Wan Hang Chiu, Chi Ho Lee, Wing Sun Chow, Alan Chun Hong Lee, Anthony Raymond Tam, Polly Pang, Tip Yin Ho, Carol Ho Yi Fong, Connie Hong Nin Loong, Wade Wei Wong, Cassandra Yuen Yan Lee, Chun Yiu Law, Kelvin K
Endocrine.2021; 74(2): 205. CrossRef
SARS-CoV-2: Emerging Role in the Pathogenesis of Various Thyroid Diseases
Avaniyapuram Kannan Murugan, Ali S Alzahrani
Journal of Inflammation Research.2021; Volume 14: 6191. CrossRef
POST-COVID ENDOCRINOPATHY :ABOUT A CASE ENDOCRINOPATHIE POST- COVID :À PROPOS D’UN CAS
S. Rafi, G. Elmghari, N, Elansari
INDIAN JOURNAL OF APPLIED RESEARCH.2021; : 13. CrossRef

First
Prev
Page of 1
Next
Last

Search